SCHEMBL6704559

SCHEMBL6704559

CCN1CCN(c2cc3c(cc2OC)CCN3)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.38
ALDH1A1 P00352 4/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP2C19 P33261 1/20 0.37
DRD3 P35462 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
ACHE P22303 1/20 0.36
GAA P10253 3/20 0.36
HTR1A P08908 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ATM Q13315 1/20 0.36
MAPT P10636 2/20 0.35
TSHR P16473 1/20 0.35
RAD52 P43351 1/20 0.35
GFER P55789 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6979693 0.86 DRD2 (0.46) DRD2ALDH1A1ALOX15CYP2C19DRD3
SCHEMBL8305064 0.83 HTR3A (0.51) DRD2CYP2C19DRD3HTR1AMAPT
SCHEMBL8126450 0.81 OPRL1 (0.43) DRD2ALDH1A1CYP2C9CYP2C19CHRM5
SCHEMBL8306947 0.76 MAPK1 (0.45) ALDH1A1CYP2C9ALOX15CYP2C19GAA
SCHEMBL6100983 0.75 GHSR (0.45) HTR1ATSHR
SCHEMBL6100980 0.75 GHSR (0.45) HTR1ATSHR
SCHEMBL6604341 0.74 HTR1B (0.45) HTR1ATSHR
SCHEMBL6100745 0.74 HTR1B (0.45) HTR1ATSHR
SCHEMBL8187738 0.73 NPC1 (0.39) DRD2ALDH1A1DRD3GAAHTR1A
SCHEMBL8187240 0.73 NPC1 (0.39) DRD2ALDH1A1DRD3GAAHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1119548-B1 3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(2-NITROPHENYL)-1H-PYRROLE-2,5-DIONE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITOR (GSK-3) SMITHKLINE BEECHAM PLC (GB) 2004-12-08 EP disclosed
US-6719520-B2 FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER SMITHKLINE BEECHAM CORPORATION 2004-04-13 US disclosed
US-20040010031-A1 Novel method and compounds SMITHKLINE BEECHAM P.L.C. 2004-01-15 US disclosed
EP-1119548-A1 PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2001-08-01 EP disclosed
WO-2000021927-A2 PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2000-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010031-A1 Novel method and compounds GSK3A, GSK3B, GSKIP DRD2 1650/4885ALDH1A1 2191/4885CYP2C9 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.